The APIP Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the human HT29 colorectal adenocarcinoma cell line, featuring disruption of the APIP gene. This product offers a loss-of-function model to study APIP??s roles in apoptosis inhibition and methionine salvage. As a polyclonal knockout, it provides a heterogeneous cell pool with ablated APIP expression, suitable for comparative functional studies with wild-type controls.
The HT29 cell line originates from a human colorectal adenocarcinoma and serves as an established in vitro model of intestinal epithelial biology. These adherent epithelial cells retain characteristics of colorectal epithelium, including the expression of intestinal markers and responsiveness to inflammatory stimuli, making them valuable for investigations of colorectal cancer pathogenesis, mucosal inflammation, and drug transport. The introduction of an APIP knockout into this background allows for targeted dissection of cell survival and metabolic pathways in a pathologically relevant context.
At the molecular level, APIP functions as an anti-apoptotic factor by directly binding APAF1, a core apoptosome component. This interaction prevents APAF1 from activating caspase-9, thereby blocking the caspase cascade. Independently, APIP acts as a methylthioribose-1-phosphate isomerase in the methionine salvage pathway, catalyzing a crucial step in methionine recycling. Upstream, APIP expression is regulated by bacterial lipopolysaccharide (LPS) and inflammatory cytokines, linking extracellular signals to apoptotic control. APIP also interacts with NLRP3, potentially integrating apoptosis and inflammasome signaling. Representative pathway components include cytochrome c, caspase-9, methionine, and methylthioribose-1-phosphate.
In the colorectal adenocarcinoma context, APIP??s anti-apoptotic role is particularly significant, as evasion of apoptosis is a cancer hallmark. HT29 cells harbor mutant TP53 but remain susceptible to apoptosis. Disruption of APIP removes a key apoptotic brake, which may sensitize cells to chemotherapeutics or death receptor ligands. Given the association of colorectal cancer with chronic inflammation, the regulation of APIP by inflammatory mediators provides a direct link between the tumor microenvironment and cell survival, enabling studies of how inflammation modulates apoptotic and metabolic pathways in tumor cells.
These knockout cells support a range of research applications. Apoptosis studies can utilize caspase-9 activity assays, Annexin V staining, and cell viability measurements, with Western blotting confirming APIP ablation. Co-immunoprecipitation with APAF1 facilitates mechanistic interrogation of protein interactions. For methionine salvage analysis, targeted metabolomics can assess intermediates like methylthioribose-1-phosphate. Drug sensitivity testing benefits from evaluating the effect of APIP loss on therapeutic responses, and inflammation experiments employ LPS or cytokine stimulation. For further details, contact Ascent Research.
